MannKind (Nasdaq:MNKD) announced today that it received FDA approval for its Afrezza inhaled insulin powder for children.

HUDSON, Wis., May 07, 2026--(BUSINESS WIRE)--Phillips Medisize, a Molex company and a leader in the design, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and ...

Resyca BV, a pioneering leader in the development and manufacturing of advanced inhalation drug delivery devices, proudly announces successful certification under the European Medical Device ...

HUDSON, Wis.--(BUSINESS WIRE)--Phillips Medisize, a Molex company and a leader in the design, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices, ...

Phillips Medisize, a contract development and manufacturing organization serving medical device and pharma OEMs acquired by Molex in 2016, announced today that it has completed the acquisition of ...

As medications advance, so do devices used for drug delivery. Pharmaceutical engineers and designers are focused on how to make drug delivery systems easier, less painful, more sustainable, and better ...

The FDA has approved the inhaled human insulin Afrezza (MannKind) for children aged 6 years or older with type 1 diabetes (T1D) or type 2 diabetes (T2D).

Inhalation therapies for respiratory disease encompass a variety of devices, chiefly pressurised metered-dose inhalers (pMDIs) and dry powder inhalers (DPIs), each with distinct environmental profiles ...

Tell us about the work you lead at AstraZeneca. I work on the development of inhalation devices for patients, mostly with COPD and asthma. There are a couple of different kinds of inhalers we are ...

Janssen is recommending physicians withhold prescribing its pulmonary arterial hypertension drug because Philips Respironics is discontinuing the only approved delivery system for the drug. Philips ...

Teva received approval for Uzedy which is a long acting risperidone to treat schizophrenia. For this drug, Teva was looking for a way to improve the patient journey and outcomes for this specific ...